Top View
- Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis
- Lemtrada (Alemtuzumab)
- Ozanimod 0.5 Mg Or 1 Mg Ozanimod Daily, Or Weekly Injections of Interferon Beta-1A
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
- View Transcript
- Updated June 2019 Original July 2014
- Self-Administered Specialty Drug List
- Lemtrada® (Alemtuzumab)
- Summary Review
- Ozanimod in Multiple Sclerosis
- Oral Therapies for MS the Advent of Oral Therapies Has Ushered in a New Phase of Disease-Modifying Treatments
- Oral Multiple Sclerosis Drugs
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Navigating the Expanding Sphingosine-1-Phosphate Receptor Modulator Armamentarium for Multiple Sclerosis Management Greater Opportunities for Patients with MS
- Assessment Report
- Mayzent (Siponimod)
- PM118 Alemtuzumab (Lemtrada)
- 5.01.565 Pharmacotherapy of Multiple Sclerosis
- Tysabri® (Natalizumab) Injection
- 209899Orig1s000
- Application Number
- 11/19/2020 Mayzent (Siponimod) Tablets. It Slow
- A Report on Comparative Safety and Efficacy of Ponesimod in the Treatment of Multiple Sclerosis (MS)
- Sphingosine 1-Phosphate Receptor Modulation Suppresses Pathogenic Astrocyte Activation and Chronic Progressive CNS Inflammation
- 1-Phosphate Axis in Cancer, Inflammation and Beyond
- April 10, 2019 Institute for Clinical and Economic Review 2 Liberty Square Boston, MA 02109 Dear ICER Review Panel, Genentech
- Multiple Sclerosis Therapy – Oral and Subcutaneous
- Metabolism and Disposition of Siponimod, a Novel Selective S1P1
- Tysabri® (Natalizumab) Injection
- Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation
- Place D'ocrevus® Dans La Thérapeutique Actuelle De
- VIRGINIA PREMIER MEDALLION 4.0 PRIOR AUTHORIZATION DETAIL September 1, 2021
- Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, In
- Ponesimod (Ponvory™) New Drug Update
- Ozanimod in Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis: Treatment Update Outline
- Prescribing Information
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Bafiertam
- Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- 209884Orig1s000
- Drugs Limited to Specific Pharmacies | Kaiser Permanente Washington
- BARMER Arzneimittelreport 2021 Arzneimitteltherapie in Der Schwangerschaft Und Bei Frauen Im Gebärfähigen Alter
- GILENYA (Fingolimod) MAVENCLAD (Cladrabine) MAYZENT (Siponimod) PONVORY (Ponesimod) TECFIDERA (Dimethyl Fumarate) VUMERITY (Diroximel Fumarate) ZEPOSIA (Ozanimod)
- Mayzent (Siponimod)
- Tecfidera™ (Dimethyl Fumarate)*, Vumerity™ (Diroximel Fumarate)*, Zeposia (Ozanimod) ®
- 213498Orig1s000
- Simcyp Publications and Independent Applications List 2020